North America Precision Oncology Market Size & Outlook
North America Precision Oncology Market, 2018-2030 (US$M)
Global Market
Related Markets
North America precision oncology market highlights
- The North America precision oncology market generated a revenue of USD 50,955.7 million in 2024.
- The market is expected to grow at a CAGR of 9.8% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 50,955.7 million |
| Market revenue in 2030 | USD 89,247.5 million |
| Growth rate | 9.8% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, North America region accounted for 44.0% of the global precision oncology market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 50,287.5 million by 2030.
The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches. For instance, in August 2024, Illumina Inc. announced the FDA approval of its TruSight Oncology comprehensive test, representing a significant advancement, analyzing over 500 genes in solid tumors to identify actionable biomarkers.
With its approval as a companion diagnostic for therapies like Bayer's VITRAKVI and Lilly's RETEVMO, the test enhances the precision of cancer care by matching patients with targeted treatments. Such innovations are propelling the growth of precision oncology in the region by improving diagnostic accuracy and expanding therapeutic options.
No credit card required*
Publish Date: Jan 22, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Exact Sciences Corp | View profile | 6,600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | www.exactsciences.com |
| Invitae Corp | View profile | 1,700 | 1400 16th Street, San Francisco, CA, United States, 94103 | www.invitae.com |
| Rain Oncology | View profile | 101-250 | Newark, California, United States, North America | www.rainoncology.com |
| Strata Oncology | View profile | 51-100 | Ann Arbor, Michigan, United States, North America | www.strataoncology.com/ |
| Xilis | View profile | 51-100 | Durham, North Carolina, United States, North America | www.xilis.net |
| Variantyx | View profile | 101-250 | Framingham, Massachusetts, United States, North America | www.variantyx.com |
| BioServe | View profile | 51-100 | Beltsville, Maryland, United States, North America | bioserve.com |
North America Precision Oncology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Oncology Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 78.01% in 2024.
Horizon Databook has segmented the North America precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches. For instance, in August 2024, Illumina Inc. announced the FDA approval of its TruSight Oncology comprehensive test, representing a significant advancement, analyzing over 500 genes in solid tumors to identify actionable biomarkers.
With its approval as a companion diagnostic for therapies like Bayer's VITRAKVI and Lilly's RETEVMO, the test enhances the precision of cancer care by matching patients with targeted treatments. Such innovations are propelling the growth of precision oncology in the region by improving diagnostic accuracy and expanding therapeutic options.
- North America Precision Oncology Market Product Outlook (Revenue, USD Million , 2018-2030)
- Diagnostics
- Therapeutics
- North America Precision Oncology Market Cancer Outlook (Revenue, USD Million , 2018-2030)
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Others
- North America Precision Oncology Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Healthcare Data Companies
Reasons to subscribe to Precision Oncology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Precision Oncology Market Outlook databook
- Our clientele includes a mix of Precision Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Precision Oncology Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Precision Oncology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
North America Precision Oncology Market, 2018-2030 (US$M)
North America Product - Precision Oncology Market Statistics, 2024 - 2030 (US$M)
